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Immunity to Human Rhinoviruses 
 
Rhinovirus (RV) infections impose a major disease burden as they cause around three out of 
four common colds and are responsible for the majority of acute exacerbations of chronic 
obstructive pulmonary disease (COPD) and asthma [1, 2]. RVs therefore are associated with 
an enormous economic cost in missed work or school and medical attention. Prophylactic 
vaccination against infection is arguably the most effective medical intervention ever 
developed, and has proven enormously effective in protecting against a large number of 
diseases. However, at the present time no effective vaccine exists for RVs. This is largely 
due to the existence of 100 serotyped antigenically distinct RV strains - such variability 
means that a vaccine designed to elicit immune responses against a particular RV is unlikely 
to be able to provide protection against the full range of virus subtypes successfully [3]. In 
fact, this phenomenon was observed as early as 1965 when immunising with formalin 
inactivated whole RV and is confirmed by the knowledge that the immunity induced following 
RV infection does not significantly protect from future infection by different RV serotypes [4]. 
More sophisticated attempts at immunisation with multiple inactivated RV serotypes also 
failed to induce significant cross-serotype protection [5]. Thus, an effective cross-serotype 
responsive RV vaccine has remained elusive. The relatively recent description of a new 
clade of RV types (RV-C) has increased the number of identified strains/serotypes to ~160 
[6]. Perhaps the quest for a RV vaccine has been dismissed as too difficult or even 
impossible, but new developments suggest that it may be feasible to generate a significant 
breadth of immune protection. 
 
 
 
Subunit Vaccines and Adjuvants 
 
The most effective existing viral vaccines are “live” formulations in which the patient is 
exposed to an attenuated form of the virus. These replicate in the body mimicking the natural 
infection without the induction of serious disease and thus lead to prolonged exposure to 
antigens, inducing protective immunity. However, live vaccines are unlikely to deliver broadly 
reactive immunity to RVs, for many of the same reasons that inactivated vaccines failed. 
 
Thus, the application of subunit vaccines, which have been developed for other significant 
human viral pathogens, such as hepatitis B virus and human papilloma virus [7], has now 
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been explored for RVs. In subunit vaccines, the immunogen comprises a small subunit or a 
virus-like particle (VLP) form of the pathogen. By their very nature these do not cause 
infection. However, most such non-infectious peptide-based vaccines are poorly 
immunogenic and rely on the presence of an adjuvant to inculcate robust immunity by 
mimicking the danger signals that naturally trigger immune responses. The addition of 
adjuvants to vaccines enhances the immunogenicity of antigens, and reduces the number of 
immunizations required. 
 
At present, inorganic compounds known as ‘alums’ (usually either AlOOH or amorphous 
aluminium hydroxyphosphate) are used as adjuvants in the vast majority of cases [8]. Alum 
can promote strong antibody responses that are effective in inducing immunity to bacteria 
and parasites (a Th2 response). However, it does not provoke strong Th1 immunity, which is 
intrinsically linked to the cellular immune responses that are most potent against intracellular 
pathogens. With respect to RVs, a Th1-biased immune response is likely to be desirable   
because human memory T cell responses to RV have been demonstrated to be primarily 
Th1 orientated [9] and memory Th1 responses were found to be protective against virus 
shedding after experimental infection [10]. RV infections are also known to enhance the Th2 
responses already found in asthma [11, 12]. A reconfiguration of this undesirable immune 
response to Th1 could alleviate RV triggered exacerbations of allergic airway diseases.  
 
Only alum, the oil-in-water emulsion adjuvants AS03 and MF59, and a new adjuvant 
containing alum and monophosphoryl lipid A (AS04) are currently licensed for use in human 
vaccines. These often do not provoke the correct pattern of immune response needed to 
most effectively target a viral disease, although mixed Th1/Th2 responses can be promoted 
by AS03 and MF59 [13]. In addition, despite the fact that it has been used for around 80 
years in the clinic, the mechanisms of action of alum are not well understood. Not for nothing 
is it known as the immunologist’s “dirty little secret” [14]. 
 
Thus in addition to the immunogen, the adjuvant represents a key challenge to developing a 
subunit RV vaccine. 
 
Novel Adjuvants and Immune Response Tailoring 
 
AlOOH is an inorganic material, but until very recently few attempts had been made to 
employ materials chemistry approaches to develop new adjuvants. However, some 
important steps forward have been taken to this end in the last 5 years. The effect of varying 
the particle size and shape of alum has been explored, and nanoparticles found to be more 
potent as adjuvants than particles on the micron scale [15]. In other work, rod shaped 
particles have been found to promote stronger immune responses than plates or polyhedra 
[8]. A range of other inorganic particles such as zinc and cobalt oxides, silver and gold 
nanoparticles have also been discovered to possess adjuvanticity [8]. In the latter case, rod 
shaped particles were again found to be more potent than other shapes. 
 
Perhaps the most exciting finding is the recent discovery that layered double hydroxides 
(LDHs), inorganic materials with compositions similar to alum, can act as potent adjuvants 
[16]. LDHs contain metal hydroxide sheets which bear a positive charge, and charge-
balancing anions between these layers. They have the general formula [Mz+1-
qM
3+
q(OH)2]
q+(Xn-)q/n·yH2O, and typically contain mixtures of mono-/di- and trivalent cations 
with the interlayer anions comprising halides, nitrate, etc. A wide variety of metal ions and 
anions can be incorporated into the LDH structure (e.g. [LiAl2(OH)6](CO3)0.5·yH2O; 
[Mg2Al(OH)6]Cl·yH2O; [Ca2Al(OH)6]NO3·yH2O).  
 
Different LDHs have been found to promote different responses across a range of cytokines 
(e.g. IL-1β, IL-6, IL-12p70), chemokines (e.g. IL-8), costimulatory molecules (CD40, CD86) 
and antibodies (e.g. IgG1, IgG2c) [16]. The latter is particularly important: some LDHs 
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stimulate IgG1 (a Th2-associated antibody) at levels similar to or greater than alum while 
others stimulate both IgG1 and IgG2c (a Th1-associated antibody) [16]. Thus, LDHs can 
drive both Th2 and Th1 responses. Moreover, it proved possible to use mathematical 
modelling to develop an equation linking the immune response provoked in vitro and in vivo 
to certain physicochemical properties of the LDHs, permitting the response induced by an 
as-yet untested adjuvant to be predicted a priori [16]. 
Other work has further shown that the [Mg2Al(OH)6]Cl·yH2O LDH conjugated with CpG can 
also drive a strong Th1 response [17]. The discovery of such advanced adjuvants offers 
great potential to incrementally tune the immune response, and might ultimately yield 
materials able to produce a particular spectrum of immune response (cytokines, 
chemokines, costimulatory molecules) at a greater level of specificity than a simple Th1/Th2 
polarisation. 
 
Recent Developments in Subunit Rhinovirus Vaccines 
 
In recent work, areas of the RV capsid proteins VP4 and VP2 (VP0) and the 3’ region of the 
viral polymerase were identified as being broadly conserved across RV serotypes [18]. 
These regions have been assessed as potential subunit immunogens to induce broadly 
reactive immunity to RV [18]. Using small animal models, immunization with RV-A16 VP0 
protein in combination with the Th1-directing incomplete Freund’s adjuvant and CpG 
promoted potent Th1 immune responses, resulting in VP0-specific T cell IFN-γ production 
and induction of antibodies which bound multiple virus serotypes [18]. Robust cross-serotype 
(both to the closely related serotype RV-A1 and importantly also distantly related serotypes 
RV-B14 and RV-A29) RV-specific Th1 responses were seen systemically after VP0 
immunisation, and also in the lungs with VP0 immunisation followed by live intranasal 
heterologous RV challenge. Furthermore, immunisation and RV challenge enhanced RV-
neutralising antibody titres and was associated with reduced viral load in vivo [18]. In other 
studies, immunisation of rabbits with the RV VP1 capsid proteins of RV-B14 or RV-A89 
generated antisera containing cross-serotype RV-neutralising antibodies that weakly 
neutralised several distantly related RV serotypes, suggesting that known regions of higher 
sequence similarity can induce cross-neutralising antibodies even though neutralising 
antibodies tend to recognise native virion structural epitopes [19]. Additionally, repeated 
immunisation of mice with inactivated RV-A1 preparations followed by live RV-A1 infection 
induced antibodies that predominantly bound VP1 of multiple serotypes, and induced weak 
(up to a 1:32 dilution) neutralising activity against RV-A16, further implicating VP1 as a 
potential vaccine candidate [20]. Thus, conserved protein antigens exist within RVs and 
these can induce cross-reactive cellular and humoral immune responses with protective 
abilities. These regions of RVs (VP0 or VP1) are applicable as candidate subunit vaccines 
for RVs and warrant further investigation. 
 
 
Future Outlook 
 
The twin discoveries of tuneable adjuvants and potential immunogens which can provide 
cross-serotype immunity to RV offer potential for future developments of a vaccine 
formulation against this widespread disease. The combination of an adjuvant able to drive a 
highly Th1 polarised response and an immunogen which could lead to broad spectrum 
protection could lead to robust protective immunity and minimal side effects in terms of 
undesirable airway inflammation in individuals suffering from RV-induced exacerbations of 
asthma - the most critical unmet medical need relevant to RVs. 
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